Gilead's NASH combination treatment fails main goal of mid-stage study

Gilead's NASH combination treatment fails main goal of mid-stage study
Reuters: Health
Gilead Sciences Inc said on Monday all combinations of its three drugs to treat non-alcoholic steatohepatitis (NASH)failed to meet the main goal of a mid-stage study, the latest in a string of failures to treat the fatty liver disease that has no approved treatment.